Catalent’s (NYSE:CTLT) purchase of Bristol-Myers Squibb’s (NYSE:BMY) oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy, will complement its existing sterile fill/finish capabilities in Belgium and its drug substance, analytical, and fill/finish capabilities in North America.
Catalent will continue to manufacture products for Bristol-Myers Squibb’s current product portfolio at the site.
Meanwhile, Bristol-Myers will maintain a presence in Italy through ongoing development and commercialization of new medicines.
Terms of the deal weren’t disclosed; the companies expect the transaction to close by the end of 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.